NCT02028221View on ClinicalTrials.gov

Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk

PHASE2CompletedINTERVENTIONAL

Enrollment

151

Participants

Timeline

Start Date

March 7, 2014

Primary Completion Date

November 30, 2018

Study Completion Date

June 14, 2022

Conditions

Breast Cancer Prevention

Interventions

DRUG

Metformin

metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the duration of he intervention period.

DRUG

Placebo

1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)

Trial Locations (1)

85719

University of Arizona, Tucson

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Arizona

OTHER

NCT02028221 - Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk | Biotech Hunter | Biotech Hunter